Regeneron aims for FDA approval of extended dosing for EYLEA HD in AMD and DME, with a decision by April 2025. Pre-filled ...

A survey collected demographic data, ocular and medical history, and responses assessing knowledge of glaucoma and cataracts ...

ATSN-201 was given regenerative medicine advanced therapy designation to treat X-linked retinoschisis, for which there ...

Mah previews a packed 2025 Annual Meeting, from the debut of SightLine to Dr. Glaucomflecken’s return to the main stage, and ...

Eyestem Research Pvt Ltd announced positive results from its phase 1/2 trial ( NCT06394232) evaluating its investigational ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Biocon Biologics and Regeneron settled to commercialize aflibercept-jbvf in the US, resolving patent litigation. The agreement allows Biocon to launch Yesafili in the US by the second half of 2026, or ...

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

A study analyzed the geographic and institutional disparities in clinical trial distribution for candidates targeting the ...

Topline data from both Phase 3 trials is expected in the second quarter of 2026, with NDA submission to follow thereafter.

In the European Union and United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular ...

Pykus Therapeutics announced it has completed enrollment in its pilot study, PYK-2101-RD00, evaluating PYK-2101, a focal ...